

Press release  
May 6, 2015

## **Invitation to a teleconference/audiocast and presentation of Aerocrine's Q1 Report 2015**

**Solna, Sweden – May 6, 2015 - Aerocrine AB (Nasdaq Stockholm: AERO) hereby invites to a teleconference/audiocast and presenting of Aerocrine's first quarter result 2015 on May 12, 2015 at 09:30 CET.**

Aerocrine will publish its report for the first quarter 2015 on May 12, 2015.

A teleconference/audiocast will be held for analysts, the media and investors on the same day at 09:30 CET. Scott Myers, CEO and Marshall Woodworth, CFO will present the report.

The presentation will be held in English and it is possible to participate by teleconference or audiocast. The audiocast can be viewed at [www.aerocrine.com](http://www.aerocrine.com), ([www.financialhearings.com](http://www.financialhearings.com)). Here you will also find the presentation material for the meeting.

For participation via the teleconference please call in five minutes prior to the specified time to ensure a punctual start to the meeting. Call in at: +46 8 566 426 61 Sweden or UK +44 203 428 14 32 or US +1 855 753 22 36. Questions can be asked verbally via the teleconference, or in writing via the audiocast. The presentation will also be available on demand at [www.aerocrine.com](http://www.aerocrine.com)

### **Welcome**

#### **For further information:**

Scott Myers, Chief Executive Officer, Aerocrine AB: +1 970 368 0336 or +46 768 788 379  
Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219

Or visit [www.aerocrine.com](http://www.aerocrine.com)

### **About Aerocrine**

*Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Nasdaq Stockholm Stock Exchange in 2007.*